News

Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination With Immunotherapy for Non-Small Cell Lung Cancer

Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria
Read More

Big Excitement in Gene Therapy at ASGCT 2019

Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22nd Annual Meeting in Washington, D.C.

Read More

Genprex Retains Addison Whitney for Drug Nomenclature Branding

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of
Read More

How Genprex Differs From “Traditional” Gene Therapy Approaches

Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work?

Read More

Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.

Read More

Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

Read More

Thermo Fisher and Brammer Bio Deal Illustrates Rapid Growth for Gene Therapy

The gene therapy market is experiencing tremendous excitement, and these acquisitions strengthen the position that gene therapy is now a significant and key treatment option for patients with serious diseases or cancer.

Read More

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

Read More

IASLC 2019: Bringing Together Collaboration, Science and Hope for the Future

The IASLC 2019 Targeted Therapies of Lung Cancer Meeting left attendees feeling energized about the incredible work being done to improve patient outcomes for those with lung cancer.

Read More